20,128 Days of Data

CHICAGO, Oct. 4, 2019 /PRNewswire/ — Dr. Steven Fox and Healthcare Analyst Joseph Person recently presented The Power and Value of Your Data to a standing room only audience at the Home Care Association of America annual meeting in Tucson, Arizona. The presentation detailed the seismic shift in medicine and healthcare from trust to doubt and prerogative to accountability. The growth and inevitable shift to value based payment and Medicare Advantage programs was addressed. The importance of real-time patient generated health data and telehealth were validated by 20,128 days of patient data through the Home Care MetricsSMprogram.

              The Home Care MetricsSMStudy
                 N=37
                 Mean Age: 86.3 (65-104 years)
                 Number of Chronic Conditions 3.8

Medicare    

HCM

           30 Day Readmission Rate      

13.9%

0.25%

           30 Day Fall Rate

36.9%

0.25%

           30 Day ER Visits Rate            

18.2%

0.93%

Home Care MetricsSM is a telehealth platform use by complex chronically ill patients to prevent and avoid hospitalizations and emergency room care.

Contact:
Steven C. Fox D.O., Home Care MetricsSM
Phone: 312-953-5202
Email: 224226@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/20-128-days-of-data-300931064.html

SOURCE Home Care Metrics

Staff

Recent Posts

Understanding When to Use Fillers or Neurotoxins According to Dr. Ran Rubinstein

Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…

1 hour ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…

1 hour ago

Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…

1 hour ago

ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…

1 hour ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Company expects up to six-month review period per FDA guidelines  New longer-term clinical data demonstrating…

1 hour ago